Top

Published in:

Open Access 01-12-2023 | Insulins | Review

The interplay between androgens and the immune response in polycystic ovary syndrome

Authors: Sania Shabbir, Emaan Khurram, Vedhika Sathya Moorthi, Youssef Tamer Hassan Eissa, Mohammad Azhar Kamal, Alexandra E. Butler

Published in: Journal of Translational Medicine | Issue 1/2023

Abstract

Polycystic ovary syndrome (PCOS) is a metabolic-reproductive-endocrine disorder that, while having a genetic component, is known to have a complex multifactorial etiology. As PCOS is a diagnosis of exclusion, standardized criteria have been developed for its diagnosis. The general consensus is that hyperandrogenism is the primary feature of PCOS and is associated with an array of physiological dysfunctions; excess androgens, for example, have been correlated with cytokine hypersecretion, adipocyte proliferation, and signaling pathway dysregulation. Another key feature of PCOS is insulin resistance, resulting in aberrant glucose and fatty acid metabolism. Additionally, the immune system plays a key role in PCOS. Hyperandrogenism stimulates some immune cells while it inhibits others, thereby disrupting the normal balance of immune cells and creating a state of chronic inflammation. This low-grade inflammation could contribute to infertility since it induces ovarian dysfunction. This dysregulated immune response in PCOS exhibits autoimmunity characteristics that require further investigation. This review paper examines the relationship between androgens and the immune response and how their malfunction contributes to PCOS.

Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–84. https://doi.org/10.1038/nrendo.2018.24.CrossRefPubMed

Polycystic ovary syndrome (PCOS). Mayo Clinic. 2020.

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487–525. https://doi.org/10.1210/er.2015-1018.CrossRefPubMedPubMedCentral

The Royal Australian College of general Practitioners. Polycystic ovary syndrome. Australian Family.

Whigham LD, Butz DE, Dashti H, Tonelli M, Johnson LK, Cook ME, et al. Metabolic evidence of diminished lipid oxidation in women with polycystic ovary syndrome. Curr Metabolomics. 2014;2(4):269–78. https://doi.org/10.2174/2213235X01666131203230512.CrossRefPubMedPubMedCentral

Baptiste CG, Battista M-C, Trottier A, Baillargeon J-P. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1–3):42–52. https://doi.org/10.1016/j.jsbmb.2009.12.010.CrossRefPubMed

Gleicher N, Weghofer A, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee H-J, et al. Is androgen production in association with immune system activation potential evidence for existence of a functional adrenal/ovarian autoimmune system in women? Reprod Biol Endocrinol. 2013;11(1):58. https://doi.org/10.1186/1477-7827-11-58.CrossRefPubMedPubMedCentral

GubbelsBupp MR, Jorgensen TN. Androgen-Induced Immunosuppression. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.00794.CrossRef

Krishnan A, Muthusami S, Periyasamy L, Stanley JA, Gopalakrishnan V, Ramachandran I. Effect of DHT-induced hyperandrogenism on the pro-inflammatory cytokines in a rat model of polycystic ovary morphology. Medicina (Kaunas). 2020;56(3):100.CrossRefPubMed

10.

Abraham Gnanadass S, Divakar Prabhu Y, Valsala GA. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet. 2021;303(3):631–43. https://doi.org/10.1007/s00404-020-05951-2.CrossRefPubMed

11.

Zafari Zangeneh F, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed (Yazd). 2017;15(6):375–82.CrossRef

12.

Bhati M, Prabhu Y, Renu K, Vellingiri B, Thiagarajan P, Panda A, et al. Role of TGF-β signalling in PCOS associated focal segmental glomerulosclerosis. Clin Chim Acta. 2020;510:244–51.CrossRefPubMed

13.

Zhang H-Y, Zhang Y-F, Han Y-K, Xue F-X, Zhao X-H, Zhang X-L. Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients. Zhonghua Fu Chan Ke Za Zhi. 2012;47(1):19–23.PubMed

14.

Ye W, Xie T, Song Y, Zhou L. The role of androgen and its related signals in PCOS. J Cell Mol Med. 2021;25(4):1825–37.CrossRefPubMed

15.

Connolly A, Leblanc S, Baillargeon J-P. Role of lipotoxicity and contribution of the renin-angiotensin system in the development of polycystic ovary syndrome. Int J Endocrinol. 2018;2018:1–13.CrossRef

16.

de Medeiros S, Barbosa B, Lin Winck Yamamoto A, Winck Yamamoto M, Soutode Medeiros M, Soares Junior J, et al. The interplay between androgens and adipocytes: the foundation of comorbidities of polycystic ovary syndrome. GREM Gynecol Reproduct Endocrinol Metab. 2022;01:02–8. https://doi.org/10.53260/grem.223011.CrossRef

17.

de Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome. Hum Reprod. 2021;27(4):771–96. https://doi.org/10.1093/humupd/dmab004.CrossRef

18.

Zhang J, Bao Y, Zhou X, Zheng L. Polycystic ovary syndrome and mitochondrial dysfunction. Reprod Biol Endocrinol. 2019;17(1):67. https://doi.org/10.1186/s12958-019-0509-4.CrossRefPubMedPubMedCentral

19.

Kuang H, Duan Y, Li D, Xu Y, Ai W, Li W, et al. The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome. PLoS ONE. 2020;15(8):e0235404. https://doi.org/10.1371/journal.pone.0235404.CrossRefPubMedPubMedCentral

20.

Akre S, Sharma K, Chakole S, Wanjari MB. Recent advances in the management of polycystic ovary syndrome: a review article. Cureus. 2022;14(8):e27689. https://doi.org/10.7759/cureus.27689.CrossRefPubMedPubMedCentral

21.

Kumar P, Arora S. Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates. J Hum Reprod Sci. 2014;7(4):255–61. https://doi.org/10.4103/0974-1208.147492.CrossRefPubMedPubMedCentral

22.

Sathyapalan T, Atkin SL. Evidence for statin therapy in polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1(1):15–22. https://doi.org/10.1177/2042018810367984.CrossRefPubMedPubMedCentral

23.

Cassidy-Vu L, Joe E, Kirk JK. Role of statin drugs for polycystic ovary syndrome. J Family Reprod Health. 2016;10(4):165–75.PubMedPubMedCentral

24.

Hu C, Pang B, Ma Z, Yi H. Immunophenotypic profiles in polycystic ovary syndrome. Mediators Inflamm. 2020;2020:5894768. https://doi.org/10.1155/2020/5894768.CrossRefPubMedPubMedCentral

25.

Figueroa F, Motta A, Acosta M, Mohamed F, Oliveros L, Forneris M. Role of macrophage secretions on rat polycystic ovary: its effect on apoptosis. J Reprod Fertil. 2015;150(5):437–48.CrossRef

26.

Ibáñez L, Jaramillo AM, Ferrer A, de Zegher F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod. 2005;20(9):2457–62. https://doi.org/10.1093/humrep/dei072. (Epub 2005 May 19).CrossRefPubMed

27.

Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. Front Immunol. 2014;5:508. https://doi.org/10.3389/fimmu.2014.00508.CrossRefPubMedPubMedCentral

28.

Lewis RD, Narayanaswamy AK, Farewell D, Rees DA. Complement activation in polycystic ovary syndrome occurs in the postprandial and fasted state and is influenced by obesity and insulin sensitivity. Clin Endocrinol (Oxf). 2021;94(1):74–84. https://doi.org/10.1111/cen.14322.CrossRefPubMed

29.

Ben-Batalla I, Vargas-Delgado ME, von Amsberg G, Janning M, Loges S. Influence of androgens on immunity to self and foreign: Effects on immunity and cancer. Front Immunol. 2020;11:1184. https://doi.org/10.3389/fimmu.2020.01184.CrossRefPubMedPubMedCentral

30.

Wu R, Fujii S, Ryan NK, Van der Hoek KH, Jasper MJ, Sini I, et al. Ovarian leukocyte distribution and cytokine/chemokine mRNA expression in follicular fluid cells in women with polycystic ovary syndrome. Hum Reprod. 2007;22(2):527–35.CrossRefPubMed

31.

Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Mol Cancer Ther. 2016;15(4):731–42. https://doi.org/10.1158/1535-7163.MCT-15-0706. (Epub 2016 Mar 3).CrossRefPubMedPubMedCentral

32.

Gallinelli A, Ciaccio I, Giannella L, Salvatori M, Marsella T, Volpe A. Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic ovary syndrome. Fertil Steril. 2003;79(6):1365–72.CrossRefPubMed

33.

Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q. Tumor necrosis factor-alpha and polycystic ovarian syndrome: a clinical, biochemical, and molecular genetic study. Genet Test Mol Biomarkers. 2014;18(9):605–9. https://doi.org/10.1089/gtmb.2014.0151.CrossRefPubMedPubMedCentral

34.

Popovic M, Schiffer L, Taylor AE, Arlt W, Vogt D, De GC, et al. Effect of IL-1 receptor antagonism on hyperandrogenemia in women with polycystic ovary syndrome. Endocr abstr. 2021;73:34.

35.

Borthakur A, Prabhu Y, Valsala GA. Role of IL-6 signalling in Polycystic Ovarian Syndrome associated inflammation. J Reprod Immunol. 2020;141:103155.CrossRefPubMed

36.

Nitulescu GM, Van De Venter M, Nitulescu G, Ungurianu A, Juzenas P, Peng Q, et al. The Akt pathway in oncology therapy and beyond (Review). Int J Oncol. 2018;53(6):2319–31. https://doi.org/10.3892/ijo.2018.4597.CrossRefPubMedPubMedCentral

37.

Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer. 2009;125(12):2863–70. https://doi.org/10.1002/ijc.24748.CrossRefPubMedPubMedCentral

38.

Luo Y, Zheng SG. Hall of fame among pro-inflammatory cytokines: Interleukin-6 gene and its transcriptional regulation mechanisms. Front Immunol. 2016;7:604. https://doi.org/10.3389/fimmu.2016.00604.CrossRefPubMedPubMedCentral

39.

Paul A, Edwards J, Pepper C, Mackay S. Inhibitory-κB kinase (IKK) α and Nuclear Factor-κB (NFκB)-inducing kinase (NIK) as anti-cancer drug targets. Cells. 2018;7(10):176. https://doi.org/10.3390/cells7100176.CrossRefPubMedPubMedCentral

40.

Liu Y, Liu H, Li Z, Fan H, Yan X, Liu X, et al. The release of peripheral immune inflammatory cytokines promote an inflammatory cascade in PCOS patients via altering the follicular microenvironment. Front Immunol. 2021;12:685724. https://doi.org/10.3389/fimmu.2021.685724.CrossRefPubMedPubMedCentral

41.

Zhuang Z, Pan X, Zhao K, Gao W, Liu J, Deng T, et al. The effect of interleukin-6 (IL-6), interleukin-11 (IL-11), signal transducer and activator of transcription 3 (STAT3), and AKT signaling on adipocyte proliferation in a rat model of Polycystic ovary syndrome. Med Sci Monit. 2019;25:7218–27. https://doi.org/10.12659/MSM.916385.CrossRefPubMedPubMedCentral

42.

Özdemir Başer Ö, Göçmen AY, Aydoğan KD. The role of inflammation, oxidation and Cystatin-C in the pathophysiology of polycystic ovary syndrome. Turk J Obstet Gynecol. 2022;19(3):229–35. https://doi.org/10.4274/tjod.galenos.2022.29498.CrossRefPubMedPubMedCentral

43.

Qi X, Yun C, Liao B, Qiao J, Pang Y. The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome. J Endocrinol. 2020;245(2):281–9.CrossRefPubMed

44.

Wang J, Gong P, Li C, Pan M, Ding Z, Ge X, et al. Correlation between leptin and IFN-γ involved in granulosa cell apoptosis in PCOS. Gynecol Endocrinol. 2020;36(12):1051–6. https://doi.org/10.1080/09513590.2020.1760817.CrossRefPubMed

45.

Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5(4):285–94.CrossRefPubMed

46.

Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS. The role of TGF-β in polycystic ovary syndrome. Reprod Sci. 2014;21(1):20–31. https://doi.org/10.1177/1933719113485294.CrossRefPubMed

47.

Attisano L, Tuen L-HS. Genome Biol. 2001;2(8):30101. https://doi.org/10.1186/gb-2001-2-8-reviews3010.CrossRef

48.

Hatzirodos N, Bayne RA, Irving-Rodgers HF, Hummitzsch K, Sabatier L, Lee S, et al. Linkage of regulators of TGF-β activity in the fetal ovary to polycystic ovary syndrome. FASEB J. 2011;25(7):2256–65. https://doi.org/10.1096/fj.11-181099.CrossRefPubMedPubMedCentral

49.

Guo R, Zheng Y, Yang J, Zheng N. Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. BMC Genet. 2015;16(1):5. https://doi.org/10.1186/s12863-015-0165-4.CrossRefPubMedPubMedCentral

50.

Prabhu Y, Valsala GA. Can polyunsaturated fatty acids regulate Polycystic Ovary Syndrome via TGF-β signalling? Life Sci. 2021;276:119416. https://doi.org/10.1016/j.lfs.2021.119416.CrossRef

51.

Prabhu Y, Bhati M, Vellingiri B, Valsala GA. The effect of γ-linolenic acid on Polycystic Ovary Syndrome associated Focal Segmental Glomerulosclerosis via TGF-β pathway. Life Sci. 2021;276:119456. https://doi.org/10.1016/j.lfs.2021.119456.CrossRef

52.

PI3K-AKT signaling pathway. Creative-diagnostics.com.

53.

Esfandyari S, Elkafas H, Chugh RM, Park H, Navarro A, Al-Hendy A. Exosomes as biomarkers for female reproductive diseases diagnosis and therapy. Int J Mol Sci. 2021;22(4):2165.CrossRefPubMedPubMedCentral

54.

Aziz E, Elham A, Sara S, Simin S, Solmaz MD, Rovshan K, Mohammad H. Current analytical approaches in diagnosis of melanoma. TrAC Trends Analyt Chem. 2019;116:122–35.CrossRef

55.

Jahanbani Y, Shafiee S, Davaran S, Roshangar L, Ahmadian E, Eftekhari A, Dolati S, Yousefi M. Stem cells technology as a platform for generating reproductive system organoids and treatment of infertility-related diseases. Cell Biol Int. 2022;46(4):512–22. https://doi.org/10.1002/cbin.11747. (Epub 2021 Dec 30 PMID: 34918417).CrossRefPubMed

56.

Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, et al. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem. 2004;279(15):14579–86. https://doi.org/10.1074/jbc.m306143200.CrossRefPubMed

57.

Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, De Falco A, et al. Rapid signalling pathway activation by androgens in epithelial and stromal cells. Steroids. 2004;69(8–9):517–22.CrossRefPubMed

58.

Walters KA. Role of androgens in normal and pathological ovarian function. J Reprod Fertil. 2015;149(4):R193-218.CrossRef

59.

Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta. 2011;1813(9):1619–33.CrossRefPubMed

60.

Liu Y, Yao Z-X, Papadopoulos V. Cytochrome P450 17alpha hydroxylase/17,20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells. Mol Endocrinol. 2005;19(7):1918–31. https://doi.org/10.1210/me.2004-0271.CrossRefPubMed

61.

Manna PR, Stetson CL, Slominski AT, Pruitt K. Role of the steroidogenic acute regulatory protein in health and disease. Endocrine. 2016;51(1):7–21. https://doi.org/10.1007/s12020-015-0715-6.CrossRefPubMed

62.

Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12. https://doi.org/10.1002/path.2697.CrossRefPubMedPubMedCentral

63.

Papa S, Choy PM, Bubici C. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene. 2019;38(13):2223–40. https://doi.org/10.1038/s41388-018-0582-8.CrossRefPubMed

64.

Chuang SM, Wang IC, Yang JL. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium. Carcinogenesis. 2000;21(7):1423–32. https://doi.org/10.1093/carcin/21.5.423.CrossRefPubMed

65.

Huang J-C, Duan C-C, Jin S, Sheng C-B, Wang Y-S, Yue Z-P, et al. HB-EGF induces mitochondrial dysfunction via estrogen hypersecretion in granulosa cells dependent on cAMP-PKA-JNK/ERK-Ca2+-FOXO1 pathway. Int J Biol Sci. 2022;18(5):2047–59. https://doi.org/10.7150/ijbs.69343.CrossRefPubMedPubMedCentral

66.

Ashraf S, Nabi M, Rasool SA, Rashid F, Amin S. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt J Med Hum Genet. 2019;20(1):1–10.CrossRef

67.

Crocitto LE, Feigelson HS, Yu MC, Kolonel LN, Henderson BE, Coetzee GA. A polymorphism in intron 6 of the CYP17 gene. Clin Genet. 1997;52(1):68–9. https://doi.org/10.1111/j.1399-0004.1997.tb02519.x.CrossRefPubMed

68.

Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer. 2000;36(18):2375–9. https://doi.org/10.1016/s0959-8049(00)00334-8.CrossRefPubMed

69.

Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994;3(10):1873–6. https://doi.org/10.1093/hmg/3.10.1873.CrossRefPubMed

70.

Dasgupta A, Banerjee U, Roy P, Khan A, Ghosh M, Chowdhuri KM. Assessment of CYP 17 gene polymorphism in subjects with polycystic ovarian syndrome and central obesity in an Indian subpopulation. Int J Hum Genet. 2014;14(1):33–41. https://doi.org/10.1080/09723757.2014.11886225.CrossRef

71.

Banerjee U, Dasgupta A, Khan A, Ghosh MK, Roy P, Rout JK, et al. A cross-sectional study to assess any possible linkage of C/T polymorphism in CYP17a1 gene with insulin resistance in non-obese women with polycystic ovarian syndrome. Indian J Med Res. 2016;143(6):739–47.CrossRefPubMedPubMedCentral

72.

Erickson GF, Hsueh AJ, Quigley ME, Rebar RW, Yen SS. Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries. J Clin Endocrinol Metab. 1979;49(4):514–9. https://doi.org/10.1210/jcem-49-4-514.CrossRefPubMed

73.

Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod. 1998;4(1):1–8. https://doi.org/10.1093/molehr/4.1.1.CrossRefPubMed

74.

Xita N, Lazaros L, Georgiou I, Tsatsoulis A. CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril. 2010;94(1):250–4. https://doi.org/10.1016/j.fertnstert.2009.01.147.CrossRefPubMed

75.

Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800. https://doi.org/10.1210/edrv.18.6.0318.CrossRefPubMed

76.

Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the insulin and elevated level of androgen: A major cause of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2021;12:741764. https://doi.org/10.3389/fendo.2021.741764.CrossRefPubMedPubMedCentral

77.

Genazzani A, Prati A, Genazzani A, Battipaglia C, Simoncini T, Szeliga A, et al. Synergistic effects of the integrative administration of acetyl-L-carnitine, L-carnitine, L-arginine and N-acetyl-cysteine on metabolic dynamics and on hepatic insulin extraction in overweight/obese patients with PCOS, GREM Gynecological and Reproductive. Endocrinol Metab. 2020;01(2020):56–63. https://doi.org/10.53260/grem.2010110.CrossRef

78.

Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. https://doi.org/10.1210/er.2015-1104.CrossRefPubMedPubMedCentral

79.

Barcellos CRG, Rocha MP, Hayashida SAY, Nery M, Marcondes JAM. Prevalence of abnormalities of glucose metabolism in patients with polycystic ovary syndrome. Arq Bras Endocrinol Metabol. 2007;51(4):601–5.CrossRefPubMed

80.

Mancini A, Bruno C, Vergani E, d’Abate C, Giacchi E, Silvestrini A. Oxidative stress and low-grade inflammation in polycystic ovary syndrome: controversies and new insights. Int J Mol Sci. 2021;22(4):1667. https://doi.org/10.3390/ijms22041667.CrossRefPubMedPubMedCentral

81.

Abudawood M, Tabassum H, Alanazi AH, et al. Antioxidant status in relation to heavy metals induced oxidative stress in patients with polycystic ovarian syndrome (PCOS). Sci Rep. 2021;11:22935. https://doi.org/10.1038/s41598-021-02120-6.CrossRefPubMedPubMedCentral

82.

Khazaei M, Aghaz F. Reactive oxygen species generation and use of antioxidants during in vitro maturation of oocytes. Int J Fertil Steril. 2017;11(2):63–70. https://doi.org/10.22074/ijfs.2017.4995. (Epub 2017 Feb 16).CrossRefPubMedPubMedCentral

83.

Mohammadi M. Oxidative stress and polycystic ovary syndrome: a brief review. Int J Prev Med. 2019;17(10):86. https://doi.org/10.4103/ijpvm.IJPVM_576_17.CrossRef

84.

Jamilian M, Samimi M, Mirhosseini N, Afshar Ebrahimi F, Aghadavod E, Talaee R, Jafarnejad S, Hashemi Dizaji S, Asemi Z. The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome. J Affect Disord. 2018;1(238):32–8. https://doi.org/10.1016/j.jad.2018.05.027. (Epub 2018 May 26).CrossRef

85.

Cheng X, He B. Clinical and biochemical potential of antioxidants in treating polycystic ovary syndrome. Int J Womens Health. 2022;1(14):467–79. https://doi.org/10.2147/IJWH.S345853.CrossRef

86.

Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Castelló R, Falcón R, Gómez M, Rocha M, Hernández-Mijares A. Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance. Eur J Endocrinol. 2015;173(5):683–91. https://doi.org/10.1530/EJE-15-0572. (Epub 2015 Aug 28).CrossRefPubMed

87.

Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2012;97(11):3951–5. https://doi.org/10.1210/jc.2012-2279. (Epub 2012 Aug 9).CrossRefPubMed

88.

Eftekhari A, Khusro A, Ahmadian E, Maleki Dizaj S, Dinparast L, Bahadori M, Hasanzadeh A, Cucchiarini M. Phytochemical and nutra-pharmaceutical attributes of Mentha spp: a comprehensive review. Arab J Chem. 2021;14:103106. https://doi.org/10.1016/j.arabjc.2021.103106.CrossRef

89.

Sadeghi M, Alaee S, Bagheri MJ, Bahmanpoor S. Role of Essential Oil of Mentha Spicata (Spearmint) in Addressing Reverse Hormonal and Folliculogenesis Disturbances in a Polycystic Ovarian Syndrome in a Rat Model. Adv Pharm Bull. 2017;7(4):651–4. https://doi.org/10.15171/apb.2017.078. (Epub 2017 Dec 31).CrossRef

90.

Lushchak O, Zayachkivska A, Vaiserman A. Metallic nanoantioxidants as potential therapeutics for type 2 diabetes: a hypothetical background and translational perspectives. Oxid Med Cell Longev. 2018;27(2018):3407375. https://doi.org/10.1155/2018/3407375.PMID:30050652;PMCID:PMC6040303.CrossRef

91.

Ali A. Polycystic ovary syndrome as an autoimmune disease: a new concept. Obstet Gynecol. 2000;95(6):S48.

92.

Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica (Cairo). 2016;2016:4071735. https://doi.org/10.1155/2016/4071735.CrossRefPubMed

Title: The interplay between androgens and the immune response in polycystic ovary syndrome
Authors: Sania Shabbir
Emaan Khurram
Vedhika Sathya Moorthi
Youssef Tamer Hassan Eissa
Mohammad Azhar Kamal
Alexandra E. Butler
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Insulins
Polycystic Ovary Syndrome
Cytokines
Polycystic Ovary Syndrome
Insulins
Androgens
Published in: Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-023-04116-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

The role of TET2-mediated ROBO4 hypomethylation in the development of diabetic retinopathy

Emerging healthy lifestyle factors and all-cause mortality among people with metabolic syndrome and metabolic syndrome-like characteristics in NHANES

hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner

ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m6A-IGF2BP2-dependent manner

Lactoferrin suppresses the progression of colon cancer under hyperglycemia by targeting WTAP/m6A/NT5DC3/HKDC1 axis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage